# MediciBIO Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medicibio-co

- Industry: Biotechnology
- Headquarters: Yongin, South Korea
- Total disclosed funding: $3.3M
- Latest round: Series A (Sep 22, 2026)
- Investors on record: 3

## About

Based in Yongin, South Korea, founded in 2021, MediciBIO Co., Ltd. operates as a company that develops lipid nanoparticle drug delivery technologies for gene-based medicines. The company creates proprietary lipid carriers that improve the delivery of RNA and DNA therapies, vaccines, and treatments for genetic diseases while aiming to reduce immune reactions and side effects.

## Funding rounds

- Series A, Sep 22, 2026, $3.3M — Kolon Investment, ES Investor, Daedeok Venture Partners

## Investors

- Kolon Investment (https://capitalatlas.ai/funds/kolon-investment) — Series A
- ES Investor (https://capitalatlas.ai/funds/es-investor) — Series A
- Daedeok Venture Partners (https://capitalatlas.ai/funds/daedeok-venture-partners) — Series A